OpenClaw for Allergy & Immunology Clinics: Shot Reminders, SLIT Compliance & Annual Test Recall (2026)

Introduction

Allergy and immunology practices run on cadence at a depth few other specialties match. A representative 2-allergist practice runs 2,500-4,000 active patients, manages a SCIT (subcutaneous immunotherapy) injection schedule for 300-700 of them on weekly build-up or monthly maintenance, oversees a SLIT (sublingual immunotherapy) panel of 80-250 patients on daily home-dose adherence, administers Xolair, Dupixent, Nucala, Fasenra, and Cinqair biologic injections on 2-4 week cycles for 60-180 patients, runs peanut OIT (Palforzia or office-based) for a growing cohort, and maintains anaphylaxis action plans and EpiPen prescriptions for every food-allergic, venom-allergic, and severe-allergic patient on the roster. The nurse coordinator and front desk are supposed to own this cadence. In reality, both roles are buried in injection scheduling, missed-dose protocol decisions, biologic prior-authorization renewal chase, EpiPen expiration tracking, and SLIT adherence outreach, and the highest-clinical-value work, the actual immunotherapy progression decisions, gets the leftover attention.

The cost is measurable. SCIT no-show rates for build-up phase injections sit at 12-22% in most practices and substantially higher for maintenance-phase patients who fall out of the habit. SLIT adherence drops sharply after the first 90 days, with industry data suggesting only 40-55% of patients complete the full 3-year course. Biologic prior authorization renewals failed or late account for a meaningful share of biologic-treated patients dropping coverage mid-year, and biologics like Xolair and Dupixent can run $30,000-$60,000 per patient per year in payer billing, so renewal lapses are not small events. EpiPen expirations not refilled in time create a medico-legal exposure no practice wants.

OpenClaw changes this without replacing the nurse coordinator. OpenClaw Consult specializes in allergy and immunology-specific implementations: AllergyEHR (Connexin), Xtract by Sublingual Solutions, AllergyOSI integration, the SCIT build-up to maintenance lifecycle, the SLIT tablet adherence cadence, biologic injection scheduling and prior-authorization renewal, peanut OIT timeline management, T.R.U.E. Test patch testing coordination, spirometry recall, and anaphylaxis action plan plus EpiPen refill cadence. The agent owns the cadence; the allergist and nurse own the clinical judgment.

For broader dermatology integration (many allergy practices overlap), see our dermatology practice guide. For the underlying compliance framework, see healthcare compliance. For platform fundamentals see Heartbeat, Memory, and Skills.

The Allergy Practice Problem

Allergy and immunology is structurally different from general internal medicine and primary care, and most automation tools sold into it were designed for one of those and retrofitted. The differences matter because they map directly to where revenue and clinical compliance leak.

The multi-year SCIT relationship. A typical SCIT patient enters the practice for diagnostic skin testing, begins build-up (weekly injections for 4-7 months), transitions to maintenance (monthly injections for 3-5 years), and discharges when the allergist determines treatment course is complete. That is potentially a 5-6 year longitudinal relationship per SCIT patient with dozens to hundreds of injection visits, each of which is a potential drop-off point.

The SLIT adherence cliff. Sublingual immunotherapy is a daily-dose home-administration commitment for 3 years. Industry data and AAAAI member surveys suggest only 40-55% of patients complete the full course, with the steepest drop-off in the 3-9 month window after the initial dose. Without an adherence outreach cadence, the practice has no early warning of patients silently discontinuing.

The biologic prior-authorization cycle. Xolair, Dupixent, Nucala, Cinqair, Fasenra, and Tezspire require initial prior authorization with documented clinical criteria and then annual or semi-annual reauthorization with documented response. Renewal lapses mean either the patient pays out of pocket (unlikely at $2,500-$5,000 per month list price), the practice eats the cost (unsustainable), or the patient discontinues therapy (clinically suboptimal). Industry estimates put preventable renewal lapses at 10-18% of treated patients annually.

The peanut OIT operational complexity. Palforzia and office-based peanut OIT require a structured up-dosing schedule with in-office observation at each up-dose, daily home maintenance dosing, and milestone visits. A practice running peanut OIT for 30-80 patients can be using 15-25% of clinical capacity on the protocol if the operational workflow is manual.

The anaphylaxis action plan and EpiPen lifecycle. Every food-allergic, venom-allergic, and severe-allergic patient should have a current Anaphylaxis Action Plan and unexpired epinephrine auto-injectors. EpiPens expire after roughly 12-18 months. Without an automated refill cadence, the practice has no way to know which patients have expired EpiPens at any given time, which creates real medico-legal exposure and worse clinical preparedness for the family.

Workflow 1: SCIT Shot Schedule

The SCIT injection schedule is the highest-volume recurring workflow in most allergy practices and the workflow where cadence discipline directly drives revenue and patient outcomes.

Sub-workflow 1.1: Build-up phase scheduling and reminders

The build-up phase (weekly injections for 4-7 months, depending on the allergist's specific schedule) is when most patients drop off. The agent maintains the per-patient build-up schedule, runs the 72-hour, 24-hour, and 2-hour reminder cadence under CPT 95115 (single injection) or 95117 (two or more injections), surfaces missed-appointment recovery same-day or next-day, and runs the missed-dose protocol decision tree per AAAAI guidelines: a missed week typically requires the next dose held at the same level; 2 missed weeks may require a one-step dose reduction; 3+ weeks typically requires a more significant reduction or restart depending on the dose at miss. The clinical decision to reduce or hold remains with the allergist; the agent surfaces the recommended dose for confirmation before the nurse prepares the injection.

Sub-workflow 1.2: Maintenance phase cadence and habit retention

Once a patient transitions to maintenance (monthly injections, typically for 3-5 years), the operational pattern shifts. The agent runs a monthly reminder cadence with light-touch messaging (the patient is in habit) and a more substantive engagement on quarterly visits when the allergist re-evaluates progress. Patients who miss 2+ months get a personal outreach from the nurse coordinator rather than another templated reminder, because the drop-off pattern at this stage is usually about life circumstances rather than forgetting.

Sub-workflow 1.3: Local and systemic reaction documentation

Local reactions (swelling, redness at the injection site) and systemic reactions (urticaria, wheezing, anaphylaxis) require documentation per AAAAI Joint Task Force parameters. The agent reads the post-injection observation note, flags reactions for allergist review, surfaces the dose-adjustment recommendation per the practice's protocol, and tracks the reaction history across the patient's course. Patients with recurring reactions or escalating reaction patterns get flagged for the allergist's specific review rather than waiting for the next scheduled visit.

Workflow 2: SLIT Compliance

Sublingual immunotherapy is the harder adherence problem because the patient does most of the work at home. The agent's job is to make home-dose adherence sustainable across a 3-year commitment.

Sub-workflow 2.1: First-dose in-office visit and SLIT initiation

FDA-approved SLIT tablets (Grastek for timothy grass, Ragwitek for short ragweed, Odactra for house dust mite, Oralair for grass mix) require the first dose to be administered in the office under observation for at least 30 minutes per the prescribing information. The agent schedules the first-dose visit, runs the pre-visit instructions (eat before, plan for 60 minutes in office, etc.), and post-visit transitions the patient to the daily-home-dose tracking cadence.

Sub-workflow 2.2: Adherence cadence (initial high frequency, then tapering)

The agent runs a high-frequency adherence cadence in the first 90 days (weekly check-ins, light-touch but specific: "Are you doing the daily dose? Any side effects we should know about?"), tapers to monthly after 90 days, and runs quarterly clinical-progress check-ins through the 3-year course. Patients who report missed doses or side effects get routed to the nurse coordinator for outreach; patients who report doing well stay on the lighter-touch cadence. The agent also runs the seasonal symptom-diary cadence (especially valuable for pollen-driven SLIT) so the allergist has data to evaluate response.

Sub-workflow 2.3: Milestone visit scheduling (12-month, 24-month, 36-month)

Each SLIT milestone visit is the opportunity for the allergist to evaluate clinical response, decide on continuation, and document compliance for ongoing prescription renewal. The agent schedules these visits at the 12-month, 24-month, and 36-month marks, runs the pre-visit symptom-diary prompt, and surfaces the patient's home-dose adherence history and seasonal symptom data to the allergist before the visit. The clinical decision to continue, modify, or discontinue stays with the allergist.

Workflow 3: Annual Test Recall

Annual skin-test recall captures patients who would otherwise drift out of the practice. The 3-5 year skin-test re-evaluation is a clinical best practice but operationally easy to miss without automation.

Sub-workflow 3.1: Skin prick test (SPT) recall and prep cadence

The agent maintains the per-patient SPT recall date, schedules the test visit, and runs the medication-hold prep cadence in the 14 days before the visit: a 14-day-out message with the medication-hold list (5-7 days off antihistamines, 14 days off some antidepressants, beta-blocker discussion if applicable per AAAAI medication-interaction tables), a 7-day-out check-in to confirm the patient has started the hold, a 24-hour-out final confirmation. Patients who cannot hold their medications get routed to ImmunoCAP IgE serum testing instead.

Sub-workflow 3.2: ImmunoCAP IgE testing coordination

For patients on medications that prevent reliable skin testing (chronic antihistamine use that cannot be held, dermatographism, severe atopic dermatitis), the agent coordinates ImmunoCAP IgE testing through the practice's reference lab. It generates the lab order, runs the patient-facing instructions for blood draw, tracks the result return, and surfaces results to the allergist with comparison to prior values when available. Food allergy panels are coordinated similarly for patients with suspected food sensitization.

Sub-workflow 3.3: Re-evaluation visit and treatment plan refresh

After the SPT or ImmunoCAP results return, the agent schedules the re-evaluation visit with the allergist, surfaces the new sensitization profile compared to the prior profile, and runs the post-visit communication cadence with any updated treatment plan (SCIT escalation, SLIT switch, biologic candidacy, etc.). For patients whose sensitization profile has changed meaningfully (new sensitizations, lost sensitizations), the allergist makes the decision; the agent runs the operational rollout.

Software & EHR Integrations

OpenClaw connects to whatever allergy-specific software the practice already runs. The major ones we have scoped:

• AllergyEHR by Connexin. One of the most widely deployed allergy-specific EHRs. Documented integration surface for schedule, allergy serum mixing log, immunotherapy injection records, and biologic injection cadence.
• Xtract by Sublingual Solutions. Specialized SLIT prescription and patient-compliance platform. The agent reads SLIT prescription data and writes back adherence outcomes.
• AllergyOSI. More constrained integration surface. Typically nightly SFTP exports of schedule, serum-vial inventory, and build-up/maintenance phase tracking.
• Generic EHRs (Epic, Cerner, athenahealth). For multi-specialty practices and academic practices where allergy is one specialty among many. Standard FHIR endpoints plus custom integration for serum-mixing and immunotherapy workflows.
• Reference labs (Quest, LabCorp, Viracor IBT). For ImmunoCAP IgE testing, food allergy panels, tryptase levels, and other allergy-relevant lab work. The agent reads order and result data through the lab's HL7 or API interface.
• Biologic specialty pharmacies. For Xolair, Dupixent, Nucala, and similar biologics that often dispense through specialty pharmacy (Accredo, CVS Specialty, Optum Specialty). The agent tracks prescription fills and prior-auth renewals.
• Twilio. The SMS and voicemail backbone. 10DLC registration handled during deployment for compliant high-volume A2P messaging.
• Patient portals (FollowMyHealth, MyChart, custom). For secure clinical content delivery where the practice prefers portal over SMS for clinical communication.
• QuickBooks Online / Xero. For AR reconciliation on patient-pay portions of immunotherapy and biologic balances.

The agent is built on the OpenClaw runtime, which means every integration is a Skill rather than a hardcoded connector. New EHR versions, new biologic products, and new SLIT or OIT therapies can be added without rebuilding the agent. The runtime's Heartbeat engine runs the scheduled flows, Memory holds the per-patient longitudinal state, and multi-agent patterns let us split SCIT, SLIT, biologic, OIT, and skin-test flows into separate reasoning agents that share state. For deeper technical detail see the API integration guide.

Biologic Injections: Xolair, Dupixent, Nucala

Biologic management is one of the most operationally complex workflows in modern allergy practice. The agent owns the operational layer across multiple products.

Xolair (omalizumab). For chronic urticaria and severe allergic asthma. Dosed every 2-4 weeks based on serum IgE and weight. The agent maintains the per-patient dosing schedule, runs the appointment cadence, manages the annual prior-auth renewal cycle, and surfaces side effects or non-response signals.

Dupixent (dupilumab). For atopic dermatitis, eosinophilic asthma, eosinophilic esophagitis, prurigo nodularis, and chronic rhinosinusitis with nasal polyps. Dosed every 2 weeks. Patient self-administration eligible after initial in-office training. The agent runs the in-office training visit cadence, transitions the patient to home-administration tracking, and manages prior-auth renewal.

Nucala (mepolizumab), Cinqair (reslizumab), Fasenra (benralizumab), Tezspire (tezepelumab). For severe eosinophilic asthma and related indications. Each has its own dosing cadence and prior-auth pattern. The agent maintains a unified biologic injection roster across all products and runs the cadence per-product.

For all biologics, the prior-authorization renewal cycle is the single most preventable revenue loss. The agent runs a 60-day-out renewal cadence: 60 days before the current authorization expires, the agent assembles the renewal package (response documentation, current symptom profile, lab values where relevant, weight for weight-based dosing), submits to the payer, and tracks the decision. Approved renewals continue uninterrupted. Denied or pending renewals get flagged to the allergist for direct payer outreach. Biologics that lapse without renewal mean the patient either eats the cost, discontinues therapy, or the practice eats the cost. None of those is good.

Peanut OIT (Palforzia & Office-Based)

Peanut oral immunotherapy is one of the highest-clinical-value emerging therapies in allergy practice and operationally one of the most demanding. The agent maintains the per-patient OIT timeline, runs the in-office up-dose visit cadence, manages the patient and family-facing daily-dose adherence cadence, surfaces reaction reports for allergist review, and runs the milestone-visit scheduling. For Palforzia specifically, the agent encodes the FDA-approved protocol: initial dose escalation in a single day under medical observation, up-dosing every 2 weeks for 22 weeks with in-office observation at each up-dose, and maintenance daily home dosing thereafter. Office-based OIT follows similar but practice-specific protocols; the agent encodes the practice's specific protocol per the allergist's design. The clinical judgment about each up-dose, reaction protocol, and continuation decision stays with the allergist.

Patch Testing T.R.U.E. Test Workflow

T.R.U.E. Test patch testing involves a 48-hour patch application, a 72-96 hour first reading, and a 5-7 day delayed reading. The three-visit pattern is operationally easy to disrupt and clinically meaningful if a reading is missed. The agent coordinates the three visits, runs the medication-hold and bathing instruction cadence, schedules the readings within the required timing window, and runs the post-test contact-allergen-avoidance education cadence for confirmed positives. The clinical interpretation of results stays with the allergist.

Spirometry & PFT Cadence

Spirometry under CPT 94010 and PFT under 94060 are routine in allergy practice for asthmatic patients. The agent maintains the asthma patient spirometry recall cadence per Joint Task Force and GINA guidelines, schedules the test visit, runs the pre-test medication-hold cadence, and surfaces test results with comparison to prior values. For persistent asthmatics on a step-up treatment trajectory, the agent flags significant declines in FEV1 or FEV1/FVC ratio for allergist review.

Anaphylaxis Action Plans & EpiPen Refills

Every food-allergic, venom-allergic, and severe-allergic patient should have a current Anaphylaxis Action Plan and unexpired epinephrine auto-injectors. The agent maintains the per-patient action plan version and expiration date, tracks each EpiPen (or Auvi-Q, Adrenaclick, generic epinephrine auto-injector) prescription expiration, runs the 60-day-out refill reminder, prepares the prescription refill request for the allergist's e-prescribing system, and runs the back-to-school anaphylaxis plan update cadence for pediatric patients in late August. The venom immunotherapy patient subgroup is tracked separately because their action-plan and EpiPen cadence is tied to the venom hypersensitivity rather than food allergy. Patients with frequent reaction events get flagged for action-plan refresh rather than waiting for the annual update.

HIPAA, AAAAI, ACAAI

Allergy practices operate under HIPAA, AAAAI and ACAAI Joint Task Force Practice Parameters, state medical board rules, TCPA for SMS, and FDA prescribing information for SLIT and OIT products. OpenClaw deployments address each layer.

HIPAA. The practice signs a BAA with the model provider and any infrastructure provider holding PHI. The agent limits SMS to scheduling and routes clinical content (lab results, ImmunoCAP values, spirometry readings, biopsy results) through the secure patient portal. See healthcare compliance and data privacy.

AAAAI and ACAAI guidelines. Joint Task Force Practice Parameters update periodically. The agent's policy memory encodes the relevant recommendations (SCIT dose-reduction tables, SLIT first-dose protocols, anaphylaxis treatment algorithms, biologic documentation patterns). When parameters update, we update the agent's memory rather than rebuilding the workflow.

FDA prescribing information. SLIT tablets, Palforzia, and biologics all have specific FDA-approved protocols. The agent encodes these and refuses to autonomously deviate.

TCPA and 10DLC. A2P messaging at the volumes a SCIT and SLIT practice produces requires 10DLC registration. We handle this during deployment.

ROI Math: Representative 2-Allergist Practice

Concrete numbers for a 2-allergist, 1-location practice running 3,200 active patients, 500 SCIT patients, 160 SLIT patients, 120 biologic patients, 45 peanut OIT patients, and 700 active EpiPen prescriptions.

Workflow	Baseline	With OpenClaw	Monthly $ Recovery
SCIT build-up drop-off	22% of 60 new starts/yr	8%	$2,100/mo (preserved 8.4 starts annualized)
SCIT no-shows (active panel)	18% of 1,500 visits/mo	6%	$5,400 (180 saved at $30 prod/visit)
SLIT 12-month adherence	52% completion	78%	$3,800 (preserved adherence-tied revenue)
Biologic PA renewal lapses	14% of 120 patients	under 2%	$6,200 (preserved practice biologic admin revenue)
Peanut OIT throughput	15-25% capacity drag	under 5% capacity drag	$3,400 (recovered chair-time and OIT growth capacity)
Annual skin-test recall	~0 systematic	+40% response on overdue	$2,800 (re-engaged patient revenue)
EpiPen refill cadence	71% coverage	96% coverage	$1,200 (e-prescription throughput, risk reduction)
Nurse coordinator capacity	5 hrs/day at $42/hr	1 hr/day same rate	$3,696/mo
Total monthly recovery (midpoint)			$28,596

Discounting heavily for overlap between workflows, the conservative net monthly recovery is $14,000-$25,000 against a one-time build cost of $22,000-$42,000 and an optional $2,000-$3,800 maintenance retainer. Payback typically lands in the first 45-90 days.

Implementation Timeline (4 Weeks)

Week 1: Discovery, EHR integration, playbook construction

• Day 1-2: Kickoff with practice owner, allergists, nurse coordinator, front desk lead. Map current workflows; identify highest-leverage starting point (usually SCIT or biologic PA).
• Day 2-4: Read-only integration with AllergyEHR, Xtract, AllergyOSI, or generic EHR. Validate the daily export and the SCIT, SLIT, biologic, and recall queries.
• Day 4-6: Build the agent's Memory schema. Load active patient roster, tag each patient with active therapies and milestone dates.
• Day 5-7: Write playbook templates with the nurse coordinator. Allergists review clinical-content templates.

Week 2: Supervised live, nurse coordinator approves every send

• Day 8-10: Twilio 10DLC registration completes. Agent runs SCIT, SLIT, and biologic cadences with nurse approval on every send.
• Day 10-12: Skin-test recall and EpiPen refill cadences go live in supervised mode.
• Day 12-14: First validation review. Measure no-show rate, adherence response, PA renewal capture.

Week 3: Validation, OIT cadence, patch testing coordination

• Day 15-17: Peanut OIT cadence and T.R.U.E. Test patch testing coordination go live.
• Day 17-19: Templates with sustained validation move toward autonomous.
• Day 19-21: Second validation review with practice owner.

Week 4: Autonomous switch, exception routing, handoff

• Day 22-24: Templates with sustained validation move to autonomous send. Clinical content and dose-adjustment decisions still route to humans.
• Day 24-26: Multi-agent routing live for practices with multiple allergists.
• Day 26-28: Team training. Documentation handoff. Monthly maintenance retainer kicks in if elected.

OpenClaw vs Patient Communication Tools vs DIY

Factor	Solutionreach / Weave / NexHealth	DIY (ChatGPT + Zapier)	OpenClaw + OpenClaw Consult
Templated reminders	Excellent	Adequate, fragile	Excellent
SCIT build-up to maintenance tracking	None	None (no state)	First-class
SLIT daily-adherence cadence	Missing	Not feasible	First-class
Biologic PA renewal chase	Missing	Not feasible	First-class
Peanut OIT timeline management	Generic appointment reminders	Possible to hack	Purpose-built
T.R.U.E. Test three-visit coordination	Templated only	Not feasible	First-class
EpiPen refill and action plan tracking	Manual	Not feasible	First-class
HIPAA + 10DLC ready	Yes	Manual, error-prone	Yes, built in
Multi-EHR support	Each covers some	Manual integration	AllergyEHR, Xtract, AllergyOSI, Epic, Cerner
Pricing (typical)	$500-$1,100/mo	Free + $20-$200/mo	$22-42k build + $2-3.8k/mo
Time-to-live	1-2 weeks templated	1-4 weeks brittle	2-4 weeks production

The right mental model: patient communication tools handle templated reminders well. OpenClaw is an agent runtime that adds the reasoning layer those tools cannot provide: SCIT phase tracking, SLIT adherence orchestration, biologic PA renewal chase, OIT timeline management, T.R.U.E. Test multi-visit coordination, and EpiPen lifecycle tracking. The combination is materially stronger than either alone.

"Our biologic PA renewal lapses dropped from one a week to almost none. That single workflow paid for the whole build inside three months. The SLIT adherence improvement is the long-term compounding piece. We are now actually finishing 3-year courses we were starting and losing." Representative quote synthesized from operator conversations we would have on scoping calls.

Why OpenClaw Consult

The OpenClaw consulting market in 2026 is full of generalist AI agencies that added allergy to their service page last quarter. OpenClaw Consult is different in three verifiable ways.

Merged contributor to openclaw/openclaw core. Founder Adhiraj Hangal (USC Computer Engineering) authored openclaw/openclaw#76345, a cost-runaway circuit breaker, merged into core by project creator Peter Steinberger in May 2026. Of approximately 41,000 people who have ever opened a PR against openclaw/openclaw, only about 6,900 have ever merged into core. No other allergy-focused OpenClaw consultant in this market has this. See best OpenClaw consultants 2026 for the broader comparison.

240+ published articles and a free 4-hour video course. The deepest public knowledge base on OpenClaw, including the vertical guides this post is part of.

Allergy-and-immunology-specific implementation experience. We have scoped AllergyEHR (Connexin), Xtract, and AllergyOSI integrations. We know the SCIT build-up and maintenance phases, the SLIT tablet protocols (Grastek, Ragwitek, Odactra, Oralair), the biologic injection cadences (Xolair, Dupixent, Nucala, Cinqair, Fasenra, Tezspire), the Palforzia and office-based peanut OIT lifecycle, the T.R.U.E. Test patch testing workflow, and the anaphylaxis action plan plus EpiPen lifecycle. Generalist agencies will deliver a chatbot. We deliver a nurse-coordinator-equivalent agent.

If your practice is evaluating an OpenClaw build, the lowest-friction next step is the hire an OpenClaw expert page or the consultant page. Engagements are fixed-scope, written before any engineering begins, with optional maintenance retainers and a 30-day handoff target.

Frequently Asked Questions

How does OpenClaw integrate with AllergyEHR (Connexin), Xtract by Sublingual Solutions, or AllergyOSI?

OpenClaw connects to allergy and immunology-specific EHR systems through whatever interface each vendor exposes. AllergyEHR (Connexin) has a documented integration surface for schedule, allergy serum mixing logs, and immunotherapy injection records. Xtract by Sublingual Solutions exposes the SLIT prescription and patient-compliance data. AllergyOSI is more constrained and typically integrates through nightly SFTP exports of the schedule, the serum-vial inventory, and the build-up vs maintenance phase tracking. In all cases the agent reads the immunotherapy schedule, the SCIT/SLIT progress, the biologic injection cadence, and the skin-test recall lists, and writes back appointment changes and recall completions through the documented API. We deliberately avoid screen-scraping the EHR UI.

Can the agent run the allergy shot reminder schedule for SCIT?

Yes, this is the highest-volume recurring workflow in most allergy practices. Subcutaneous immunotherapy (SCIT) under CPT 95115 (single injection) and 95117 (two or more injections) requires a build-up phase (typically weekly visits for 4-7 months) and a maintenance phase (typically monthly visits for 3-5 years). The agent maintains the per-patient injection schedule, runs the appointment reminder cadence at 72 hours, 24 hours, and 2 hours out, surfaces missed-dose protocol decisions when a patient is overdue (per AAAAI guidelines, a missed dose may require a dose reduction depending on the interval since the last injection), and tracks the patient's progression through the build-up to maintenance milestone. The actual dose-adjustment decision stays with the allergist.

How does OpenClaw handle SLIT compliance for tablet therapy?

Sublingual immunotherapy with FDA-approved tablets (Grastek for timothy grass, Ragwitek for short ragweed, Odactra for house dust mite, Oralair for grass mix) is a 3-year daily-dose commitment with the first dose administered in the office under observation. The agent maintains the per-patient SLIT timeline, runs the in-office first-dose appointment confirmation, sends the daily-adherence cadence (initially weekly, dropping to monthly after the first 90 days), surfaces adherence drops to the allergist for outreach, runs the 12-month, 24-month, and 36-month checkpoint visit scheduling, and tracks the seasonal symptom-diary cadence that helps the allergist evaluate response. The clinical decision to continue, escalate, or discontinue SLIT stays with the allergist.

Can the agent handle the build-up vs maintenance dose adjustment workflow for SCIT?

It handles the operational layer of dose adjustments, not the clinical decision. AAAAI and Joint Task Force on Practice Parameters guidelines specify dose-reduction protocols when patients miss SCIT doses (interval-based reductions for missed weeks), local reaction adjustments, and systemic reaction protocols. The agent reads the dose-adjustment recommendation from the previous injection note, surfaces the recommended dose to the nurse for the next visit, validates the prepared dose against the recommendation, and flags any discrepancy for the allergist before injection. The actual decision to reduce, hold, or escalate remains with the prescribing allergist.

How does the agent handle the annual skin-test recall for established patients?

Many established allergy patients benefit from a periodic re-evaluation of their sensitization profile, typically every 3-5 years depending on clinical course. The agent maintains the annual or every-few-years skin prick test (SPT) recall, schedules the test visit with appropriate medication-hold instructions (5-7 days off antihistamines, 14 days off some antidepressants and beta-blockers per AAAAI medication-interaction tables), runs the prep cadence with the medication-hold reminders, and confirms the patient has met the medication-hold criteria before the test visit. The agent also coordinates ImmunoCAP IgE testing through the practice's reference lab when serum testing is preferred to skin testing (patients on antihistamines they cannot hold, dermatographism, etc.).

Does the agent handle biologic injection cadence for Xolair, Dupixent, Nucala, and similar?

Yes, biologic injections are one of the most operationally complex workflows in modern allergy practice. Xolair (omalizumab) for chronic urticaria and severe allergic asthma is dosed every 2-4 weeks based on IgE level and weight. Dupixent (dupilumab) for atopic dermatitis and eosinophilic asthma is dosed every 2 weeks. Nucala (mepolizumab), Cinqair (reslizumab), and Fasenra (benralizumab) for severe eosinophilic asthma have their own cadences. The agent maintains the per-patient biologic injection schedule, runs the appointment cadence, manages the prior-authorization renewal cycle (most biologics require annual reauthorization with documented response), tracks the injection administration in the office or the patient self-administration at home for the at-home eligible biologics, and surfaces side effect or non-response signals to the allergist.

Can the agent run peanut OIT cadence for Palforzia or office-based OIT?

Yes. Palforzia is the FDA-approved peanut oral immunotherapy product with a structured initial dose escalation (single-day, hospital-administered), up-dosing phase (every 2 weeks for 22 weeks, in-office observation), and maintenance phase (daily home dosing with periodic in-office visits). Office-based OIT (peanut, tree nut, milk, egg, etc.) follows similar but practice-specific protocols. The agent maintains the per-patient OIT schedule, runs the in-office observation visit cadence, manages the patient and family-facing daily-dose adherence cadence, surfaces reaction reports for allergist review, and runs the milestone-visit scheduling. The clinical judgment about each up-dose, reaction protocol, and continuation decision stays with the allergist.

How does OpenClaw handle patch testing T.R.U.E. Test workflow?

T.R.U.E. Test (Thin-layer Rapid Use Epicutaneous patch test) is the standard FDA-approved 35-allergen patch test for contact dermatitis evaluation. The workflow involves a 48-hour patch application, a 72-96 hour first reading, and a 5-7 day delayed reading. The agent coordinates the three-visit pattern: schedules the application visit, runs the medication-hold and bathing instruction cadence, schedules the 48-hour and 72-96 hour reading visits within the required timing window, and runs the post-test contact-allergen-avoidance education cadence for confirmed positive readings. The clinical interpretation of patch test results stays with the allergist.

Does the agent handle spirometry and pulmonary function test workflow?

Yes. Spirometry under CPT 94010 and PFT under 94060 are routine in allergy practice for asthmatic patients. The agent maintains the asthma patient spirometry recall cadence (typically every 3-6 months for persistent asthmatics, annual for well-controlled mild asthmatics per Joint Task Force and GINA guidelines), schedules the test visit, runs the pre-test medication-hold cadence (short-acting bronchodilators held for 4-8 hours, long-acting per allergist preference), and surfaces test results to the allergist with comparison to prior values. The clinical interpretation and treatment adjustment stay with the allergist.

How does OpenClaw handle anaphylaxis action plans and EpiPen refill cadence?

Every food-allergic, severe-allergic, and venom-allergic patient should have a current Anaphylaxis Action Plan and unexpired epinephrine auto-injectors. The agent maintains the per-patient action plan version and expiration date, tracks each EpiPen (or Auvi-Q, Adrenaclick, generic epinephrine auto-injector) prescription expiration, runs the 60-day-out refill reminder, prepares the prescription refill request for the allergist's e-prescribing system, and runs the back-to-school anaphylaxis plan update cadence for pediatric patients (typically late August). The agent also runs the venom immunotherapy patient subgroup separately because their action-plan and EpiPen cadence is tied to the venom hypersensitivity rather than food allergy.

Is the agent HIPAA compliant given that allergy practices handle pediatric PHI extensively?

Yes. OpenClaw deployments in allergy practices run on a Business Associate Agreement with the model provider, log every interaction with patient ID rather than full demographics, and route any clinical content (lab results, ImmunoCAP IgE values, spirometry readings) through the secure patient portal rather than SMS. SMS communication is limited to appointment time, doctor, and office address. For pediatric patients, all clinical communication routes to the parent or guardian. See our healthcare compliance guide for the full framework.

What does OpenClaw cost for a representative 2-allergist practice?

A 2-allergist, 1-location practice running 2,500-4,000 active patients with a significant SCIT and SLIT panel typically scopes a fixed-fee build in the $22,000-$42,000 range covering EHR integration (AllergyEHR, Xtract, or AllergyOSI), SCIT and SLIT cadence, biologic injection management, peanut OIT, skin-test recall, anaphylaxis action plan tracking, and EpiPen refill cadence. Optional monthly maintenance retainer runs $2,000-$3,800. High-volume venom OIT, food OIT, or research-active practices scope higher. See our consulting cost guide for the full pricing breakdown.

How does the agent handle ACAAI and AAAAI guideline updates?

AAAAI (American Academy of Allergy, Asthma & Immunology) and ACAAI (American College of Allergy, Asthma & Immunology) publish Joint Task Force Practice Parameters that update periodically. The agent's policy memory encodes the relevant recommendations (SCIT dose-reduction tables, SLIT first-dose protocols, anaphylaxis treatment algorithms, biologic prior-authorization documentation patterns). When a Joint Task Force parameter updates, we update the agent's memory rather than rebuilding the workflow. The agent's templates and cadences inherit the updates automatically.

Why hire OpenClaw Consult specifically for an allergy and immunology implementation?

OpenClaw Consult is the only OpenClaw consultancy whose founder, Adhiraj Hangal (USC Computer Engineering), has shipped a merged pull request into openclaw/openclaw core (PR #76345, a cost-runaway circuit breaker merged by project creator Peter Steinberger in May 2026), published a free 4-hour OpenClaw video course, and written 240+ articles on the runtime. For allergy and immunology specifically, the firm has scoped AllergyEHR, Xtract, and AllergyOSI integrations, knows the SCIT build-up and maintenance phases, the SLIT tablet protocols, the biologic injection cadences, and the peanut OIT lifecycle. Generalist AI agencies sell chatbots. We deliver a nurse-coordinator-equivalent agent.

Conclusion

The allergy and immunology practices that will compound through 2026 and 2027 are not the ones that hire a second nurse coordinator. They are the ones that amplify their existing staff with an agent that owns the cadence, frees the clinical judgment, and runs the SCIT, SLIT, biologic, OIT, and anaphylaxis-preparedness workflows the standard of care implies but no human can sustain at scale across a 3,000-patient panel. OpenClaw is the runtime; the right consultant is the difference between a chatbot and a working system.

Start with SCIT no-show recovery if you start with one workflow; it is the highest dollar per hour of build time. Add biologic prior-authorization renewal within the first 30 days; it prevents the most expensive preventable revenue loss in the practice. Add SLIT adherence by month two; it compounds into 3-year completion rates that improve clinical outcomes and protect billable visits. By the end of the first year, the nurse coordinator is doing nurse work, the front desk is doing front desk work, the agent is doing the cadence chase, and the practice has the operating leverage of one more headcount at a fraction of the cost.

Ready to scope it? Apply through openclawconsult.com/hire or read the hire an OpenClaw expert guide. We respond within 24 hours and turn around a fixed-scope proposal within 5 business days.